CD8A and Hepatic fibrosis: These findings may provide potential new targets for immunotherapy aimed at activating HBV-specific CD8+ T cells, which may promise a cure for HBV-associated liver fibrosis (Bertoletti and Kennedy, 2019; Hoogeveen et al., 2019; Du et al., 2022).